Lulizumab pegol (

INN Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway; before the advent of motorized transportation they also provided accommo ...

; development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases.Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol
''

American Medical Association The American Medical Association (AMA) is a professional association and lobbying group of physicians and medical students. Founded in 1847, it is headquartered in Chicago, Illinois. Membership was approximately 240,000 in 2016. The AMA's state ...

''. This drug was developed by

Bristol-Myers Squibb The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the lar ...

References

Monoclonal antibodies Bristol Myers Squibb {{monoclonal-antibody-stub